Gilead Sciences, Inc. (NASDAQ:GILD)
A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
sunnyspot
(55.22)
Submitted: 2/5/2012 12:46:17 PM :
Start Price:
$54.30
GILD Score:
-1.30
Intelligent acquisitions, a stellar management team and a bulging pipeline spell rising fortunes for this company.
Recs
Lisinvestment
(66.33)
Submitted: 1/6/2012 10:08:28 PM :
Start Price:
$42.38
GILD Score:
+22.02
This is tracking porfortlio of the 20 stock I pick for 2012...
Recs
portefeuille
(99.81)
Submitted: 12/15/2011 11:15:49 PM :
Start Price:
$33.04
GILD Score:
+36.96
There are currently 420 GILD shares in my "fund" with break-even of around 36.36 USD. http://caps.fool.com/Blogs/fund-trades/678775.
Recs
solanZRaider
(< 20)
Submitted: 11/21/2011 10:05:17 AM :
Start Price:
$35.85
GILD Score:
+37.47
Anvil13
Recs
scootertrader
(50.60)
Submitted: 10/18/2011 3:53:51 PM :
Start Price:
$40.85
GILD Score:
+21.79
This stock looks to really take off vs. other biotechs.
Recs
skat5
(93.03)
Submitted: 10/10/2011 1:40:01 PM :
Start Price:
$36.29
GILD Score:
+36.33
eva momentum value
Recs
StockDocStan
(< 20)
Submitted: 9/9/2011 10:50:44 AM :
Start Price:
$38.38
GILD Score:
+25.85
Just wait until the quad pill is approved, and (finally) the other acquisitions start to show a diversifying pipeline!
Recs
gilboy7
(< 20)
Submitted: 8/10/2011 7:31:43 PM :
Start Price:
$35.65
GILD Score:
+32.14
Oversold on panic. New HIV drug will lift revenue. I am putting real money to work on GILD at this price.
Recs
darrylbrizan
(95.58)
Submitted: 5/29/2011 9:33:33 PM :
Start Price:
$41.16
GILD Score:
+28.22
demographics
Recs
StocknDoc
(< 20)
Submitted: 3/21/2011 2:56:54 PM :
Start Price:
$40.43
GILD Score:
+29.31
Gilead Sciences inc.: I began accumulating shares on November 19th, 2010. The stock is up 8.6% and continues toigrow, making at a great value stock. It's Beta is low which eliminates a lot of stress for those of you who prefer a stock that provides steady growth, rather than huge swings in the stocks price. Gilead is a 4 star stock in my book.
Recs
healthcarevalue
(96.24)
Submitted: 3/9/2011 12:47:35 PM :
Start Price:
$41.71
GILD Score:
+27.45
Gilead Sciences Inc., located in California, 4,000 employees, a biopharmaceutical company, acceptable debt/equity ratio at 0.59, impressive profit margins, price/earnings of 12.53, market cap of 33.08 billion. Niche products which make the company's growth prospects attractive at this stock price include: infectious disease focus, specifically HIV, chronic hepatitis, and influenza.
Recs
pcstuck
(32.85)
Submitted: 3/7/2011 10:46:50 AM :
Start Price:
$41.09
GILD Score:
+29.07
Stocks seems very cheap. Solid company that seems unfairly valued. Diversification into cancer treatment could create huge new revenue streams. Clean balance sheet and still room to grow. I think now is a great time to get in
Recs
spacebased
(75.19)
Submitted: 2/20/2011 8:30:47 AM :
Start Price:
$38.90
GILD Score:
+37.24
It's time for a run. Solid company that has technical weakness to be exploited now in merger fever season for biotechs.
Recs
Recs
FoolSolo
(75.39)
Submitted: 1/12/2011 8:19:16 AM :
Start Price:
$37.30
GILD Score:
+39.30
GILD has been on my watch list for a while, even before it was recommended by SA. The massive drop from $50 in early 2010 threw me off, but SA managed to catch the bottom very nicely. The more recent pullback has provided us with yet another nice entry point. So I'm adding it to my portfolio.
Recs
CarolinaMatt
(29.81)
Submitted: 1/3/2011 6:57:07 PM :
Start Price:
$36.87
GILD Score:
+40.26
Yes I get it. This company is no longer the high-flying early-stage pharma star with a everything under patent and profits growing as fast as it can ramp distribution.
But this is no old super-slow moving huge pharma company (i.e. Pfizer) either. Pricing is at a 2011 PE of about 9X which suggests maturity and minimal EPS growth. But this company is still projected to grow EPS at 15ish% over the next 3-5 years. Even if they fall short and come in at more like 10-11% EPS gains it is a bargain in the drug space.
Recs
MAURY56
(39.55)
Submitted: 12/31/2010 5:03:15 PM :
Start Price:
$36.64
GILD Score:
+40.66
HIV is a growth area.
Recs
Easternlethal
(< 20)
Submitted: 12/28/2010 2:19:16 AM :
Start Price:
$36.40
GILD Score:
+40.94
Good fundamentals. Support at $36 and turning up. Will also be a good defensive play when the general market corrects.
Recs
nomo001
(< 20)
Submitted: 12/27/2010 9:03:53 PM :
Start Price:
$36.40
GILD Score:
+40.94
Strong drug portfolio and pipeline. Stock is underestimated by Wall Street.
Recs
magicseeker
(58.73)
Submitted: 12/14/2010 5:09:29 PM :
Start Price:
$36.99
GILD Score:
+37.34
Solid MFI stock, CAPS 5 stars, cmon, what a gimme.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 268 : 1 2 3 4 5 6 7 8 9 10 Next »